Prophylactic Staphylococcus aureus subunit vaccine shows promising results
Intercell AG has been informed by its strategic partner Merck & Co., Inc. that a Phase I study of a recombinant subunit vaccine to prevent Staphylococcus aureus infections is progressing with promising results. The vaccine is based on a conserved protein antigen discovered by Intercell's Antigen Identification Program (AIP®) and licensed to Merck & Co., Inc. on an exclusive world wide basis in 2003.
"The fact that a vaccine based on our antigen discovery platform has delivered promising data in humans underlines the scientific and commercial potential of Intercell's technology platforms", states Alexander von Gabain, CSO of Intercell. "It is our strategy to develop our own vaccine candidates based on our technologies, and also to partner with the best players in the field to create significant value."
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.